Phase II Study Demonstrates Consistent Safety Profile for Investigational Drug
Interim findings from an ongoing Phase II clinical trial indicate that the investigational drug continues to demonstrate a stable and predictable safety profile. Across the enrolled participants, adverse events remained within anticipated ranges and aligned with preclinical and early-phase trial data. Researchers emphasize that consistent safety outcomes across dosing cohorts strengthen confidence in the study’s […]